GA-LDV: A Promising Derivative of 18β-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties

Jiaying Zheng,1,* Qiqi Feng,1,* Qi Gao,1 Yaonan Wang,1 Shurui Zhao,1 Xiaoyi Zhang,1 Ming Zhao1,2 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, Peo...

Full description

Saved in:
Bibliographic Details
Main Authors: Zheng J, Feng Q, Gao Q, Wang Y, Zhao S, Zhang X, Zhao M
Format: Article
Language:English
Published: Dove Medical Press 2025-04-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/ga-ldv-a-promising-derivative-of-18-glycyrrhetinic-acid-with-enhanced--peer-reviewed-fulltext-article-DDDT
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849701687078420480
author Zheng J
Feng Q
Gao Q
Wang Y
Zhao S
Zhang X
Zhao M
author_facet Zheng J
Feng Q
Gao Q
Wang Y
Zhao S
Zhang X
Zhao M
author_sort Zheng J
collection DOAJ
description Jiaying Zheng,1,&ast; Qiqi Feng,1,&ast; Qi Gao,1 Yaonan Wang,1 Shurui Zhao,1 Xiaoyi Zhang,1 Ming Zhao1,2 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China; 2Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, 100026, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Ming Zhao, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China, Tel +861083911535, Fax +861083911533, Email maozhao@126.com Xiaoyi Zhang, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, No. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, People’s Republic of China, Tel +861083911530, Fax +861083911533, Email zhangdd@ccmu.edu.cnPurpose: The clinical translation of 18β-Glycyrrhetinic acid (GA) is impeded by its relatively low antitumor potency and poor aqueous solubility, we developed a novel derivative of GA by incorporating the Leu-Asp-Val (LDV) tripeptide to enhance its anti-tumor and anti-metastatic activities both in vitro and in vivo, thereby increasing its potential as a therapeutic agent for cancer treatment.Methods: The water solubility of GA-LDV was evaluated. The inhibitory effects of GA-LDV on cell viability were assessed in four different human cancer cell lines. In vitro assays were conducted to measure the compound’s impact on tumor cell adhesion, migration, and invasion. In vivo studies were performed using S180 and LLC xenograft models to evaluate the tumor inhibition and anti-metastatic properties.Results: GA-LDV water solubility was increased 4.1 folds compared with GA. In vitro assays suggested that GA-LDV, at a concentration of 25 μM, significantly impeded the adhesion, migration, and invasion of LLC tumor cell lines, with inhibition rates of 52.7%, 55.5% (vs GA 16.9%, P < 0.05) and 35.9% (vs GA 27.5%, P < 0.05). Moreover, GA-LDV demonstrated stronger tumor inhibition ability than GA (P < 0.05), and anti-metastasis activities in a dose-dependent manner, at the concentration of 5 μmol/kg/d, 1 μmol/kg/d, 0.2 μmol/kg/d with lung metastatic nodules 7.5 (P < 0.01 compared with the control group), 9.8 (P < 0.05 compared with the control group) and 14.5. And GA-LDV had almost no systemic toxicity in S180 or LLC xenograft models.Conclusion: The newly synthesized GA-LDV derivative demonstrates superior water solubility and significantly enhanced anti-tumor and anti-metastatic activities. The in vitro and in vivo studies indicate that GA-LDV is a promising candidate for further development as a cancer therapeutic agent, with the benefit of potentially reduced systemic toxicity. Keywords: 18β-Glycyrrhetinic acid, anti-tumor, anti-metastasis activity, lung cancer, MMP
format Article
id doaj-art-d5e1c4fbf2204e88abec3529c65f2d55
institution DOAJ
issn 1177-8881
language English
publishDate 2025-04-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj-art-d5e1c4fbf2204e88abec3529c65f2d552025-08-20T03:17:52ZengDove Medical PressDrug Design, Development and Therapy1177-88812025-04-01Volume 1926412652101793GA-LDV: A Promising Derivative of 18&beta;-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer PropertiesZheng JFeng QGao QWang YZhao SZhang XZhao MJiaying Zheng,1,&ast; Qiqi Feng,1,&ast; Qi Gao,1 Yaonan Wang,1 Shurui Zhao,1 Xiaoyi Zhang,1 Ming Zhao1,2 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China; 2Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, 100026, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Ming Zhao, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China, Tel +861083911535, Fax +861083911533, Email maozhao@126.com Xiaoyi Zhang, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, No. 10, Youanmenwaixitoutiao, Fengtai District, Beijing, 100069, People’s Republic of China, Tel +861083911530, Fax +861083911533, Email zhangdd@ccmu.edu.cnPurpose: The clinical translation of 18β-Glycyrrhetinic acid (GA) is impeded by its relatively low antitumor potency and poor aqueous solubility, we developed a novel derivative of GA by incorporating the Leu-Asp-Val (LDV) tripeptide to enhance its anti-tumor and anti-metastatic activities both in vitro and in vivo, thereby increasing its potential as a therapeutic agent for cancer treatment.Methods: The water solubility of GA-LDV was evaluated. The inhibitory effects of GA-LDV on cell viability were assessed in four different human cancer cell lines. In vitro assays were conducted to measure the compound’s impact on tumor cell adhesion, migration, and invasion. In vivo studies were performed using S180 and LLC xenograft models to evaluate the tumor inhibition and anti-metastatic properties.Results: GA-LDV water solubility was increased 4.1 folds compared with GA. In vitro assays suggested that GA-LDV, at a concentration of 25 μM, significantly impeded the adhesion, migration, and invasion of LLC tumor cell lines, with inhibition rates of 52.7%, 55.5% (vs GA 16.9%, P < 0.05) and 35.9% (vs GA 27.5%, P < 0.05). Moreover, GA-LDV demonstrated stronger tumor inhibition ability than GA (P < 0.05), and anti-metastasis activities in a dose-dependent manner, at the concentration of 5 μmol/kg/d, 1 μmol/kg/d, 0.2 μmol/kg/d with lung metastatic nodules 7.5 (P < 0.01 compared with the control group), 9.8 (P < 0.05 compared with the control group) and 14.5. And GA-LDV had almost no systemic toxicity in S180 or LLC xenograft models.Conclusion: The newly synthesized GA-LDV derivative demonstrates superior water solubility and significantly enhanced anti-tumor and anti-metastatic activities. The in vitro and in vivo studies indicate that GA-LDV is a promising candidate for further development as a cancer therapeutic agent, with the benefit of potentially reduced systemic toxicity. Keywords: 18β-Glycyrrhetinic acid, anti-tumor, anti-metastasis activity, lung cancer, MMPhttps://www.dovepress.com/ga-ldv-a-promising-derivative-of-18-glycyrrhetinic-acid-with-enhanced--peer-reviewed-fulltext-article-DDDT18β-glycyrrhetinic acidanti-tumoranti-metastasis activitylung cancermmp
spellingShingle Zheng J
Feng Q
Gao Q
Wang Y
Zhao S
Zhang X
Zhao M
GA-LDV: A Promising Derivative of 18&beta;-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
Drug Design, Development and Therapy
18β-glycyrrhetinic acid
anti-tumor
anti-metastasis activity
lung cancer
mmp
title GA-LDV: A Promising Derivative of 18&beta;-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
title_full GA-LDV: A Promising Derivative of 18&beta;-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
title_fullStr GA-LDV: A Promising Derivative of 18&beta;-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
title_full_unstemmed GA-LDV: A Promising Derivative of 18&beta;-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
title_short GA-LDV: A Promising Derivative of 18&beta;-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
title_sort ga ldv a promising derivative of 18 beta glycyrrhetinic acid with enhanced in vitro and in vivo anti cancer properties
topic 18β-glycyrrhetinic acid
anti-tumor
anti-metastasis activity
lung cancer
mmp
url https://www.dovepress.com/ga-ldv-a-promising-derivative-of-18-glycyrrhetinic-acid-with-enhanced--peer-reviewed-fulltext-article-DDDT
work_keys_str_mv AT zhengj galdvapromisingderivativeof18betaglycyrrhetinicacidwithenhancedinvitroandinvivoanticancerproperties
AT fengq galdvapromisingderivativeof18betaglycyrrhetinicacidwithenhancedinvitroandinvivoanticancerproperties
AT gaoq galdvapromisingderivativeof18betaglycyrrhetinicacidwithenhancedinvitroandinvivoanticancerproperties
AT wangy galdvapromisingderivativeof18betaglycyrrhetinicacidwithenhancedinvitroandinvivoanticancerproperties
AT zhaos galdvapromisingderivativeof18betaglycyrrhetinicacidwithenhancedinvitroandinvivoanticancerproperties
AT zhangx galdvapromisingderivativeof18betaglycyrrhetinicacidwithenhancedinvitroandinvivoanticancerproperties
AT zhaom galdvapromisingderivativeof18betaglycyrrhetinicacidwithenhancedinvitroandinvivoanticancerproperties